Related Experiment Video
Updated: May 18, 2026
08:12
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Myeloproliferative neoplasm animal models.
Ann Mullally1, Steven W Lane, Kristina Brumme
1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hematology/Oncology Clinics of North America
|September 27, 2012
Summary
Animal models are crucial for studying myeloproliferative neoplasms (MPN), mimicking human disease in mice. These models, including genetically engineered and xenograft types, aid in understanding MPN biology and developing therapies.
Area of Science:
- Hematology
- Oncology
- Animal Models
Background:
- Myeloproliferative neoplasms (MPN) are a group of cancers affecting blood cell production.
- Animal models are essential for studying MPN pathogenesis and evaluating therapeutic strategies.
- Key genetic abnormalities like JAK2V617F are frequently observed in MPN.
Purpose of the Study:
- To review the utility of various animal models in understanding MPN.
- To highlight the role of these models in characterizing genetic abnormalities and their impact on hematopoietic stem and progenitor cells (HSPCs).
- To discuss the application of different model systems for studying MPN biology and therapy.
Main Methods:
- Transplantation of transduced bone marrow (e.g., BCR-ABL).
- Development of genetically engineered mouse models (transgenic, knock-in).
- Utilization of xenograft models for studying human MPN cells.
Main Results:
- MPN animal models accurately recapitulate human disease characteristics.
- Genetically engineered models allow detailed study of specific genetic mutations (e.g., JAK2V617F) in HSPCs.
- Xenograft models enable in vivo investigation of human MPN-propagating cells.
Conclusions:
- Animal models are indispensable tools for advancing MPN research.
- These models facilitate the comprehensive study of MPN-associated genetic alterations and their functional consequences.
- Continued development and application of diverse MPN models are vital for therapeutic innovation.
